SESSION III - 11:00 AM to 12:30 PM

Session Code: TEC


John A. Galdo (Jake), PharmD, MBA, BCPS, BCGP
Director, Education and Program Development, Pharmacy Quality Alliance


How do consumers perceive the role of community pharmacists today versus the future? Are consumers increasing their level of comfort with receiving various tests and services at pharmacies, including potential testing and treatment for COVID-19? This session will cover trends in the Consumer Survey portion of the Annual PQS Trend Report in Pharmacy Quality representing responses from nearly 1,000 consumers and the actions community pharmacies may take in response to their changing behavior.

Session Code: T1


Todd Sega, PharmD
Senior Vice President, Development and Strategy, Pharmacy Quality Solutions


Community pharmacy performance-based payment models are now commonplace. Little research has evaluated pharmacy-level drivers of this performance, particularly for Medicaid. If a better understanding of drivers of adherence are identified, this can inform pharmacy practices changes which optimize adherence performance. Additionally, threats to validity exist for both the measurement of adherence at the patient level and the accuracy of conclusions that can be made from pharmacy-level performance assessment.

This session will explore questions on validity and drivers of performance using results from a number of studies. Patient-level threats to validity that may inflate adherence as measured by proportion of days covered include automatic refills and 90-day fills. Challenges to validity of pharmacy-level performance measurement include many environmental, demographic, and clinical factors which influence adherence scores and cannot be controlled by pharmacists. Despite these challenges, studies exploring the relationship between adherence support services find services such as multidose compliance packaging and home medication delivery do find correlation between offering these services and higher adherence performance scores.

From these studies, we recommend that new adherence measure development focus on measures which are resistant to bias. Additionally, robust risk adjustment is needed to account for environmental, clinical, and demographic factors outside of a pharmacist’s control. Finally, research is needed to evaluate the impact of pharmacy services on measures of adherence to identify drivers across a variety of populations.


1. Discuss validity at the pharmacy level
2. Describe challenges to validity of adherence measurement
3. Explore drivers of pharmacy-level performance on adherence measures

Session Code: T2-B1-B

ACPE UAN: 0221-9999-20-248-L04-P
Contact Hours of Credit: 0.5


Ben Urick, PharmD, PhD
Research Assistant Professor, UNC Eshelman School of Pharmacy
Joel Farley, PhD
Professor, University of Minnesota College of Pharmacy
Monali Bhosle, PhD
Director, Pharmacy Advanced Analytics, CPESN USA, Community Care of NC


Utilization of a population health care model has been implemented within many health care systems to address the complex care needs for a variety of patient groups. Key elements of this practice include, interdisciplinary collaboration, risk stratification, care management, strong data and continues evaluation. Within our value-based care model these elements are powered by an ecosystem delivering real time data. This allows for meaningful care coordination, patient engagement, disease state management, including timely medication interventions. Pharmacist led medication management for high risk patients is driven by AI risk stratification based on claims data, predictive analytics and SDOH. Medication Therapy Problem (MTP) category framework is the tool used to collect and evaluate medication related issues. Attendance of this program will provide insight regarding medication management in a population health management care model and evaluation of MTP category framework.


1. Define the pharmacist's role in population health management at a large academic medical center.
2. Propose management strategies for gaps in care as it relates to medication use, access, and patient characteristics.
3. Evaluate the role of MTP category framework in population health management practice model.

Session Code: T3-Q2-E

ACPE UAN: 0221-9999-20-249-L04-P
Contact Hours of Credit: 0.35


Klodiana Myftari, PharmD, BCACP
Assistant Professor of Pharmacy Practice, Midwestern University
Vidya Chakravarthy, MS-HSM
Director of Population Health, Rush University Medical Center

SESSION IV - 1:30 PM to 3:00 PM


PQA members are prioritizing care and shifting resources to address COVID-19. This session will discuss current efforts, opportunities to close quality gaps in the second half of the year, and approaches to measuring quality for 2020. We’ll explore long-term ideas for measuring and rewarding quality care during viral outbreaks and other disruptions to care.

Session Code: TGS-2


Laura Cranston, RPh
Chief Executive Officer, Pharmacy Quality Alliance
Susan Cantrell, RPh CAE
Chief Executive Officer, Academy of Managed Care Pharmacy
Ceci Connolly
President and CEO, Alliance of Community Health Plans

Sponsored by

    • Excellence in Quality and Quality Improvement Awards
    • Healthcare Quality Innovation Challenge – sponsored by Pharmacy Quality Solutions
    • Community Pharmacy Innovation in Quality (CPIQ) Awards – presented by PQA and the Community Pharmacy Foundation
    • Annual Meeting Poster Session Awards

Session Code: TAW


Pharmacies today have to adapt to a rapidly changing healthcare environment while continuing to improve quality care measures. This environment is rooted in a traditional physical pharmacy location with deeply personal patient connections, yet is moving swiftly to support a consumer-driven culture of digital convenience.

This session shows how to maximize patient touchpoints to deliver omnichannel programs that work in partnership with payers to increase adherence and quality ratings.

Areas of discussion will include:

1. A payer partnership pilot leveraging bi-directional data exchange to create a better patient experience, driving higher engagement and better outcomes.
2. Collaboration with a health system to create an innovative solution supporting vulnerable populations.
3. The use of advanced analytics to bring high-touch personalized solutions to patients that need it most.
4. A discussion highlighting how expanded prescriptive authority can influence outcomes.


1. Identify innovative programs leveraging new technology to deliver higher quality ratings.
2. Describe how a partnership approach can improve patient experience leading to better outcomes.
3. Discuss how combining digital interventions, analytics and high-touch personal care from pharmacists practicing at the top of their license can increase patient engagement and improve adherence

Session Code: T4-B2-E

ACPE UAN: 0221-9999-20-250-L04-P
Contact Hours of Credit: 0.5


Mike Umbleby, RPh
Vice President, Clinical Performance, Walgreens Co.
Dorothy (Chrzaszcz) Loy, PharmD, MBA
Director of Clinical Performance Strategy, Walgreens Co.